Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;30(1):1-8.
doi: 10.1097/MOU.0000000000000683.

Developments in MRI-targeted prostate biopsy

Joseph M Norris  1 , Adam Kinnaird, Daniel J Margolis, Anwar R Padhani, Jochen Walz, Veeru Kasivisvanathan
Affiliations
Review

Developments in MRI-targeted prostate biopsy

Joseph M Norris et al. Curr Opin Urol. 2020 Jan.

Abstract

Purpose of review: MRI-targeted prostate biopsy may be an attractive alternative to systematic biopsy for diagnosing clinically significant prostate cancer. In this narrative review, we discuss the new developments that have occurred in the advancement of MRI-targeted prostate biopsy, over the past 24 months.

Recent findings: MRI-targeted biopsy offers enhanced diagnostic accuracy, when compared with the current standard of care of systematic transrectal ultrasound-guided (TRUS) biopsy, by decreasing the overall number of biopsies needed, maintaining or improving significant prostate cancer detection, and reducing the detection of clinically insignificant prostate cancer. The necessity of combining systematic prostate biopsy with MRI-targeted biopsy is still debated. The use of MRI--ultrasound fusion systems for lesion-targeting is promising for optimizing significant cancer detection, but recent evidence suggests that additional cognitive biopsy cores are still useful in detecting additional cancers.

Summary: MRI-targeted biopsy in selected men with positive MRI offers a number of benefits over systematic biopsy in all men, and as such, may emerge as the new standard of care for the diagnosis of clinically significant prostate cancer.

PubMed Disclaimer

References

    1. Kasivisvanathan V, Rannikko AS, Borghi M, et al. PRECISION Study Group CollaboratorsMRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378:1767–1777.
    1. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. PROMIS study groupDiagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389:815–822.
    1. Panebianco V, Barchetti G, Simone G, et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what's next? Eur Urol 2018; 74:48–54.
    1. Radtke JP, Wiesenfarth M, Kesch C, et al. Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer-patient-tailored risk stratification can reduce Unnecessary biopsies. Eur Urol 2017; 72:888–896.
    1. Mehralivand S, Shih JH, Rais-Bahrami S, et al. A Magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. JAMA Oncol 2018; 4:678–685.

Publication types